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Olmsted Syndrome Caused by a Heterozygous  
p.Gly568Val Missense Mutation in TRPV3 Gene
Ji Young Choi, Song-Ee Kim, Sang Eun Lee, and Soo-Chan Kim
Department of Dermatology, Cutaneous Biology Research Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 
Korea. 
Olmsted syndrome (OS) is a rare congenital skin disorder characterized by severe palmoplantar and periorificial keratoderma, 
alopecia, onychodystrophy, and severe pruritus. Recently, pathogenic ‘gain-of-function’ mutations of the transient receptor po-
tential vanilloid 3 gene (TRPV3), which encodes a cation channel involved in keratinocyte differentiation and proliferation, hair 
growth, inflammation, pain and pruritus, have been identified to cause OS. Due to the rarity, the pattern of inheritance of OS is 
still unclear. We report a case of OS in a 3-year-old Korean girl and its underlying gene mutation. The patient presented with a dis-
abling, bilateral palmoplantar keratoderma with onychodystrophy. She also exhibited pruritic eczematous skin lesions around 
her eyes, ears and gluteal fold. Genetic analysis identified a heterozygous p.Gly568Val missense mutation in the exon 13 of 
TRPV3. To our knowledge, this is the first case of OS in the Korean population showing a missense mutation p.Gly573Ser.
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INTRODUCTION
Olmsted syndrome (OS, OMIM 614594) is a rare genoderma-
tosis characterized by mutilating palmoplantar keratoderma, 
periorificial keratotic plaques, and severe itching.1,2 Patients 
suffer also from diffuse alopecia, constricting digital bands, 
and onychodystrophy.2,3 To date, approximately 70 cases of 
OS have been reported. Most cases are sporadic; however, fa-
milial OS has also been found.1,4,5 Pathogenic mutations in the 
transient receptor potential vanilloid 3 gene (TRPV3) are the 
cause of autosomal-dominant OS. TRPV3 is a thermosensitive 
cation nonselective channel predominantly expressed in ke-
ratinocytes and sensory neurons.6 Gain-of-function muta-
tions in TRPV3 lead to constitutive activity in mutant channels, 
resulting in enhanced keratinocyte apoptosis and hyperkera-
tosis.4 Herein, we report a first Korean case of Olmsted syn-
drome harboring a relatively rare missense mutation within 
TRPV3, p.Gly568Val.
CASE REPORT
A 3-year-old girl visited our department with severe bilateral 
palmoplantar hyperkeratosis. Thick, yellowish hyperkeratotic 
plaques with a foul odor were found on both palms and soles 
(Fig. 1A and B). She also had thin, brittle nails on all fingers and 
toes (Fig. 1C), and thin and sparse scalp hairs. The hyperkera-
totic lesions initially developed as several punctuate hyper-
keratotic plaques, gradually extending to the entire palmoplan-
tar surface. There was yellowish hyperkeratosis on her gluteal 
fold (Fig. 1D). Multiple hyperkeratotic papules with erythema-
tous, eczematous patches were noted around her eyes, ears 
and nose (Fig. 1E). She complained of intense pruritus, causing 
sleep disturbance. She also had walking difficulty due to pain 
of the plantar lesions.
Her height and weight were below the 3rd percentile for her 
age. Complete blood counts and routine chemistry panels re-
vealed no abnormalities. Her parents were unaffected. A skin 
biopsy from the coccygeal lesion revealed hyperkeratosis, oc-
casional parakeratosis, hypergranulosis, acanthosis, papillo-
matosis and follicular plugging with dilated vessels and in-
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flammatory infiltrates of lymphocytes, histiocytes and eosi-
nophils (Fig. 2A and B) in the upper dermis. Toluidine blue 
stains showed increased numbers of mast cells in the dermis 
(Fig. 2C). Electron microscopy showed multiple, variable-sized 
electron-lucent lipid vacuoles in the hyperkeratotic horny layer 
(Fig. 2D and E), and numerous polysome-like structures in 
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Fig. 1. Skin lesions at the initial clinical presentation. Diffuse severe keratoderma on (A) the palmar and (B) the plantar surfaces. (C) Onychodystrophy 
of all fingernails. (D) Periauricular hyperkeratotic papules with eczematous patches. (E) Hyperkeratotic yellowish plaques on the gluteal fold.
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Fig. 2. Skin biopsy features. (A and B) Hyper- and parakeratosis, hypergranulosis, irregular acanthosis and follicular plugging. Dilated vessels with in-
flammatory cellular infiltrates of lymphocytes, histiocytes and eosinophils in the upper dermis (hematoxylin-eosin, ×100 and ×200, respectively). (C) 
Increased number of mast cells in the upper dermis (toluidine blue, ×400). (D) Electron microscopy shows numerous lipid droplets in the corneocytes. 
Parakeratotic corneocytes are also noted (×2K). (E) Electron-lucent lipid droplets are observed, but corneodsmosomes are well preserved (arrows) 
(×40K). (F) Increased number of polysomes in the keratinocytes of the upper spinous layer (×20K).
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the upper spinous layer (Fig. 2F).
Genomic DNA was extracted from the peripheral blood of 
the patient and her parents. Sanger sequencing using primers 
that spanned all exons and exon-intron boundaries (NM_ 
001258205.1) identified a heterozygous G>T transversion at 
position c.1703 in exon 13 of TRPV3, which leads to the con-
version of a glycine residue to valine (p.Gly568Val) (Fig. 3) 
(primers are listed in Supplementary Table 1, only online). 
This mutation was not identified in the unaffected parents, in-
dicating a de novo mutation. We did not discover this muta-
tion on 50 healthy Korean controls. The patient showed mod-
erate improvement after treatment with a systemic acitretin, 
antihistamine, topical antibacterial, steroid ointment and 
moisturizer.
DISCUSSION
To our knowledge, this report describes the first Korean case 
of OS with a rare pathogenic mutation, p.Gly568Val, in the 
TRPV3 gene. Mutations in TRPV3 causing OS have been iden-
tified in five different amino acid residues, comprising p.
Gly568, p.Gly573, p.Leu673, p.Trp692, and p.Asn415_Arg416.3-9 
TRPV3 contains six transmembrane domains (S1–S6), and 
p.Gly573 which is within the linker region between S4-S5 is 
the most commonly reported mutation to date in TRPV3.3 Mu-
tations at codon 568, like our case, have been reported in only 
four OS cases so far; the heterozygous missense mutations at 
p.Gly568Val and p.Gly568Asp and a splice site mutation at p.
Gly568Cys.9-11 The amino acid Gly568 also resides within the 
linker between S4–S5, but near the boundary of S4 and is highly 
conserved across several species.10 Previous in silico analysis 
confirmed that the same amino acid substitution in TRPV3 
identified in our patient renders the selectivity filter of this ion 
channel more hyperpermeable.11 Therefore, this variant can be 
classified as pathogenic (PS1).12
No consistent genotype-phenotype correlations for muta-
tions in the TRPV3 gene are known yet. Notably, a substantial 
phenotypic diversity in TRPV3-related OS has been reported, 
even in families whose members share the same mutation, in 
terms of the severity and extent of the palmoplantar keratoder-
ma and the presence or absence of other hyperkeratotic le-
sions.10 Indeed, a brazillian OS patient with p.Gly568Val showed 
mild phenotype such as focal and mild keratodermas, where-
as a Japanese case and our patient harboring the same muta-
tion presented diffuse and severe symptoms.10,11 These findings 
suggest a possibility that additional genetic modifiers or envi-
ronmental factors may affect the phenotype.
In addition to its role as a thermosensor, TRPV3 plays a sig-
nificant role in mediating itch and pain sensation and regulat-
ing keratinocyte proliferation and differentiation, hair growth, 
wound healing, and inflammation.13 Several ‘gain-of-function’ 
mutations in the TRPV3 gene in OS patients were confirmed 
to exaggerate calcium influx, epidermal turnover, and apopto-
sis in keratinocytes. Many polysome-like structures that are re-
vealed by electron microscopy may reflect a stimulation of ke-
ratinocytes proliferation, which results in the massive acantho-
sis and hyperkeratosis. In addition, numerous lipid droplets in 
the corneocytes that are similar to the structural abnormalities 
in the stratum corneum (SC) of genodermatoses such as Neth-
erton syndrome, lamellar ichthyosis, congenital ichthyosiform 
erythroderma, and other erythrodermic disorders such as 
erythrodermic psoriasis may suggest the disturbed cornifica-
tion with severe perturbation of SC barrier function in OS.14,15 
Similar to the TRPV3 transgenic mice, the lesional skin of our 
patient showed increased mast cells which may trigger cuta-
neous inflammation and severe itch.
Currently, there are no effective treatments for OS. Topical 
treatments including emollients, keratolytics, retinoids, corti-
costeroids, systemic retinoids, and methotrexate provide only 
temporary symptom relief.3 Our case was moderately improved 
by low-dose systemic retinoids and topical corticosteroid. Re-
cently, fatty acid-derived pro-resolvents have been found to 
modulate the activities of transient receptor potential ion 
Fig. 3. Genetic analysis identified a heterozygous missense mutation in c.1703G>T of exon 13 of transient receptor potential vanilloid-3 (TRPV3) (p.Gly-
568Val) in the patient’s DNA, but not in either parent.
Patient
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channels. Bang, et al.16 reported 17(R)-resolvin D1, a member 
of docosahexaenoic acid-derived series of resolvins, can spe-
cifically suppress TRPV3-mediated activity. Specific inhibitors 
of TRPV3, such as 17(R)-resolvin D1, could be a promising, 
biocompatible therapeutic approach for OS in the future. Al-
though TRPV3 mutations were identified as a cause of OS, the 
exact pathomechanism is still poorly understood. Further 
studies on the pathogenesis of this unique disease might lead 
to the development of more effective treatments.
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